October 28, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: | Sonia Bednarowski |
Justin Dobbie
Sasha Parikh
Angela Connell
Re: | Oyster Point Pharma, Inc. |
Registration Statement on FormS-1
FileNo. 333-234104
Acceleration Request
Requested Date: Wednesday, October 30, 2019
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Oyster Point Pharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on FormS-1 (FileNo. 333-234104) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan Baier at (212)497-7736.
[Signature page follows]
Securities and Exchange Commission
October 28, 2019
Page 2
Sincerely, |
OYSTER POINT PHARMA, INC. |
/s/ Jeffrey Nau |
Jeffrey Nau, Ph.D., M.M.S. |
President and Chief Executive Officer |
cc: | Daniel Lochner, Oyster Point Pharma, Inc. |
Tony Jeffries, Wilson Sonsini Goodrich & Rosati, P.C.
Megan Baier, Wilson Sonsini Goodrich & Rosati, P.C.
Jennifer Fang, Wilson Sonsini Goodrich & Rosati, P.C.
Brian J. Cuneo, Latham & Watkins LLP
Nathan Ajiashvili, Latham & Watkins LLP